KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Other Non-Current Assets (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Other Non-Current Assets data on record, last reported at $460.7 million in Q1 2025.

  • For Q1 2025, Other Non-Current Assets rose 33.3% year-over-year to $460.7 million; the TTM value through Mar 2025 reached $460.7 million, up 33.3%, while the annual FY2025 figure was $461.4 million, 29.92% up from the prior year.
  • Other Non-Current Assets reached $460.7 million in Q1 2025 per TAK's latest filing, up from $345.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $948.0 million in Q1 2021 and bottomed at $345.6 million in Q1 2024.
  • Average Other Non-Current Assets over 5 years is $588.8 million, with a median of $478.7 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: crashed 32.65% in 2023, then soared 33.3% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $948.0 million in 2021, then decreased by 25.01% to $710.9 million in 2022, then tumbled by 32.65% to $478.7 million in 2023, then fell by 27.81% to $345.6 million in 2024, then skyrocketed by 33.3% to $460.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $460.7 million in Q1 2025, $345.6 million in Q1 2024, and $478.7 million in Q1 2023.